BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

CEL-SCI Corporation 

8229 Boone Boulevard
Suite 802
Vienna  Virginia  22182  U.S.A.
Phone: 703-506-9460 Fax: 703-506-9471


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
University of Minnesota Masonic Cancer Center Joins CEL-SCI (CVM)’s Phase 3 Head & Neck Cancer Trial 9/10/2014 10:25:22 AM
CEL-SCI (CVM) Enrolls 20 Patients In August In Its Phase 3 Immunotherapy Head And Neck Cancer Trial 9/3/2014 9:09:02 AM
CEL-SCI (CVM) Expands Its Global Phase 3 Immunotherapy Head And Neck Cancer Trial Into Centre Hospitalier Universitaire De Quebec In Canada 8/19/2014 8:52:45 AM
CEL-SCI (CVM) Reports Third Quarter Fiscal 2014 Financial Results 8/11/2014 8:48:09 AM
CEL-SCI (CVM) Reports Third Quarter Fiscal 2014 Financial Results 8/8/2014 3:47:54 PM
CEL-SCI (CVM) Achieves Milestone In July With Total Of 232 Patients Enrolled To Date In Its Phase 3 Head And Neck Cancer Trial 8/1/2014 10:44:38 AM
CEL-SCI (CVM) Has Been Cleared to Begin Patient Enrollment 7/23/2014 12:59:40 PM
CEL-SCI (CVM) Expands Its Phase 3 Head And Neck Cancer Trial Into Sri Lanka 7/17/2014 7:57:45 AM
CEL-SCI (CVM) Receives $225,000 National Institutes of Health (NIH) Research Grant To Develop Rheumatoid Arthritis Treatment 7/15/2014 7:45:53 AM
CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria 7/8/2014 6:39:05 AM
12345678910...